Ras mutations are among the most common oncogene mutations found in multiple myeloma (MM). Patients with mutated Ras are less likely to respond to chemotherapy and have a shortened median survival. Therefore, targeting Ras farnesylation may be a valuable approach to treatment of MM. R115777 (tipifarnib) is a potent farnesyltransferase inhibitor (FTI) presently undergoing phase II/III clinical trials.
Methods
We reviewed the preclinical and clinical experience of FTIs as antineoplastic agents and describe their potential role in the treatment of MM.
Results
FTIs are a novel group of agents that selectively inhibit farnesyltransferase, an enzyme responsible for the posttranslational modification of several proteins including Ras. Since Ras is among the most commonly mutated oncogenes associated with cancer, this class of drugs has been evaluated in clinical trials in a diversity of tumors. R115777 has been evaluated in a phase II clinical trial in patients with advanced myeloma and found to be well tolerated. It induced disease stabilization in more than 60% of patients with advanced myeloma.
Conclusions
The drug selectively targets farnesyltransferase, but this effect did not correlate with disease stabilization, suggesting that these drugs may be targeting a survival pathway independent of Ras processing. Further studies will evaluate the use of FTI in maintenance therapy as well as in combination with other agents in advanced myeloma.
References
1.
AndersonK.C.. Targeting myeloma cell-host bone marrow interactions.American Society of Clinical Oncology 2002 Education Book.2002: 79–486.
2.
DamianoJ.S., CressA.E., HazlehurstL.A.. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.Blood.1999; 93: 1658–1667.
3.
ShainK.H., DaltonW.S.. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR.Mol Cancer Ther.2001; 1: 69–78.
4.
MichigamiT., ShimizuN., WilliamsP.J.. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.Blood.2000; 96: 1953–1960.
5.
OgataA., ChauhanD., TeohG.. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.J Immunol.1997; 159: 2212–2221.
6.
HideshimaT., NakamuraN., ChauhanD.. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene.2001; 20: 5991–6000.
7.
PuthierD., BatailleR., AmiotM.. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway.Eur J Immunol.1999; 29: 3945–3950.
8.
CorradiniP., LadettoM., VoenaC.. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.Blood.1993; 81: 2708–2713.
9.
AdjeiA.A.. Blocking oncogenic Ras signaling for cancer therapy.J Natl Cancer Inst.2001; 93: 1062–1074.
SebtiS., HamiltonA.D.. Inhibitors of prenyl transferases.Curr Opin Oncol.1997; 9: 557–561.
12.
KohlN.E.. Farnesyltransferase inhibitors: preclinical development.Ann N Y Acad Sci.1999; 886: 91–102.
13.
FeldkampM.M., LauN., RoncariL.. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.Cancer Res.2001; 61: 4425–4431.
14.
ShiY., GeraJ., HsuJ.H.. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.Mol Cancer Ther.2003; 2: 563–572.
15.
LobellR.B., OmerC.A., AbramsM.T.. Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitors combinations in preclinical models.Cancer Res.2001; 61: 8758–8768.
16.
KamasaniU., LiuA.X., PrendergastG.C.. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.Cancer Biol Ther.2003; 2: 273–280.
17.
LiebermanR., BermejoC., AkazaH.. Progress in prostate cancer chemoprevention: modulators of promotion and progression.Urology.2001; 58: 835–842.
JohnstonS.R., KellandL.R.. Farnesyl transferase inhibitors: a novel therapy for breast cancer.Endocr Relat Cancer.2001; 8: 227–235.
20.
KurzrockR., KantarjianH.M., CortesJ.E.. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting.Blood.2003. In press.
21.
KarpJ.E., LancetJ.E., KaufmannS.H.. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial.Blood.2001; 97: 3361–3369.
ZhangF.L., CaseyP.J.. Protein prenylation: molecular mechanisms and functional consequences.Annu Rev Biochem.1996; 65: 241–269.
24.
LiuP., LeongT., QuamL.. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.Blood.1996; 88: 2699–2706.
25.
BezieauS., DevilderM.C., Avet-LoiseauH.. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.Hum Mutat.2001; 18: 212–224.
26.
KalakondaN., RothwellD.G., ScarffeJ.H.. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.Blood.2001; 8: 1555–1560.
27.
VenetM., EndD., AngibaudP.. Farnesyl protein transferase inhibitor ZARNESTRA R115777: history of a discovery.Curr Top Med Chem.2003; 3: 1095–1102.
28.
EndD.W., SmetsG., ToddA.V.. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.Cancer Res.2001; 61: 131–137.
29.
SmithV., RowlandsM.G., BarrieE.. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.Clin Cancer Res.2002; 8: 2002–2009.
30.
DempkeW.C.. Farnesyltransferase inhibitors: a novel approach in the treatment of advanced pancreatic carcinomas.Anticancer Res.2003; 23: 813–818.
31.
CrulM., de KlerkG.J., SwartM.. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.J Clin Oncol.2002; 20: 2726–2735.
32.
AdjeiA.A., CroghanG.A., ErlichmanC.. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.Clin Cancer Res.2003; 9: 2520–2526.
33.
JohnstonS.R., HickishT., EllisP.. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.J Clin Oncol.2003; 21: 2492–2499.
34.
AdjeiA.A., MauerA., BruzekL.. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.J Clin Oncol.2003; 21: 1760–1766.
35.
CohenS.J., HoL., RanganathanS.. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.J Clin Oncol.2003; 21: 1301–1306.
36.
BolickS.C., LandowskiT.H., BoulwareD.. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.Leukemia.2003; 17: 451–457.
37.
OchiaiN., UchidaR., FuchidaS.I.. Effect of farnesyl transferase inhibitor R115777 (Zarnestra) on the growth of fresh and cloned myeloma cells in vitro.Blood.2003: July 3. Epub ahead of print.
38.
MackleyP.A., ShainK.H., DaltonW.S.. Farnesyl transferase inhibitor R115777 decreases Akt phosphorylation in multiple myeloma cell lines and its apoptotic effects correlate with phosphoAKT expression levels.Blood.2002: 3198. Abstract.
39.
AlsinaM., FonsecaR., WilsonE.F.. The farnesyl transferase inhibitor Zarnestra is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.Blood.2003. Submitted.
40.
SalmonS.E., CrowleyJ.J., GroganT.M.. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.J Clin Oncol.1994; 12: 2405–2414.
41.
JiangK., CoppolaD., CrespoN.C.. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.Mol Cell Biol.2000; 20: 139–148.
